TSG101 and Flotillin-1 typical EV-markers have been described that are elevated in HCC patients and associated with HCC progression 39,40, appearing TSG101 slightly upregulated in cirrhotic patients from our proteomics analysis. This evidence concerns the gene FLOT1 and hepatocellular carcinoma.